Showing 37 to 48 of 171 results
Cytomegalovirus Infection Improves Melanoma Immunotherapy Response
An Oxford University study published in Nature Medicine reveals that prior cytomegalovirus infection significantly improves melanoma immunotherapy response in approximately 400 patients, leading to better outcomes and suggesting new avenues for treatment.
Cytomegalovirus Infection Improves Melanoma Immunotherapy Response
An Oxford University study published in Nature Medicine reveals that prior cytomegalovirus infection significantly improves melanoma immunotherapy response in approximately 400 patients, leading to better outcomes and suggesting new avenues for treatment.
Progress
36% Bias Score
Groundbreaking Cancer Therapy Shows Remarkable Success in Late-Stage Prostate Cancer
A California study of 15 men with late-stage prostate cancer showed that 53% achieved complete remission using SYNC-T, a novel therapy involving tumor cryotherapy followed by localized immunotherapy; this exceeded expected survival rates, offering new hope for patients with limited treatment options...
Groundbreaking Cancer Therapy Shows Remarkable Success in Late-Stage Prostate Cancer
A California study of 15 men with late-stage prostate cancer showed that 53% achieved complete remission using SYNC-T, a novel therapy involving tumor cryotherapy followed by localized immunotherapy; this exceeded expected survival rates, offering new hope for patients with limited treatment options...
Progress
48% Bias Score
Creon Shortage Cripples UK Cancer Patients
A critical shortage of Creon, a pancreatic enzyme needed by over 61,000 UK patients, is causing severe hardship, forcing patients to ration medication and impacting their treatment. The shortage, lasting over a year, is due to European-wide manufacturing issues despite government interventions.
Creon Shortage Cripples UK Cancer Patients
A critical shortage of Creon, a pancreatic enzyme needed by over 61,000 UK patients, is causing severe hardship, forcing patients to ration medication and impacting their treatment. The shortage, lasting over a year, is due to European-wide manufacturing issues despite government interventions.
Progress
40% Bias Score
Camizestrant Shows Significant Promise in Treating Aggressive Breast Cancer
A clinical trial shows that the drug camizestrant significantly reduces the risk of progression or death in patients with HR-positive HER2-negative breast cancer who have the ESR1 mutation, a common cause of treatment resistance; the drug is being fast-tracked for approval in the US and UK.
Camizestrant Shows Significant Promise in Treating Aggressive Breast Cancer
A clinical trial shows that the drug camizestrant significantly reduces the risk of progression or death in patients with HR-positive HER2-negative breast cancer who have the ESR1 mutation, a common cause of treatment resistance; the drug is being fast-tracked for approval in the US and UK.
Progress
56% Bias Score
Exercise Improves Colon Cancer Survival by 37%, Study Shows
A Canadian study of 889 colon cancer patients showed that a structured three-year exercise program reduced mortality risk by 37% compared to an educational control group, establishing exercise as a new cancer treatment modality.
Exercise Improves Colon Cancer Survival by 37%, Study Shows
A Canadian study of 889 colon cancer patients showed that a structured three-year exercise program reduced mortality risk by 37% compared to an educational control group, establishing exercise as a new cancer treatment modality.
Progress
40% Bias Score
Exercise, Diet, and New Drug Show Promise in Combating Colorectal Cancer
New studies show that regular exercise and an anti-inflammatory diet significantly improve survival rates for colorectal cancer patients, while a new drug, Braftovi, doubled survival time for patients with an aggressive form of the disease in clinical trials.
Exercise, Diet, and New Drug Show Promise in Combating Colorectal Cancer
New studies show that regular exercise and an anti-inflammatory diet significantly improve survival rates for colorectal cancer patients, while a new drug, Braftovi, doubled survival time for patients with an aggressive form of the disease in clinical trials.
Progress
16% Bias Score
UK Cancer Survival Doubles Since 1970s, But Remains Leading Killer
A report reveals that UK cancer survival has doubled since the 1970s, with half of those diagnosed surviving 10+ years, but cancer remains the UK's biggest killer, with over 460 daily deaths, and early diagnosis rates have stagnated for a decade.
UK Cancer Survival Doubles Since 1970s, But Remains Leading Killer
A report reveals that UK cancer survival has doubled since the 1970s, with half of those diagnosed surviving 10+ years, but cancer remains the UK's biggest killer, with over 460 daily deaths, and early diagnosis rates have stagnated for a decade.
Progress
48% Bias Score
New 'Smart Bomb' Cancer Treatment Shows Significant Improvement in HER2-Positive Metastatic Breast Cancer
A clinical trial involving nearly 400 patients with HER2-positive metastatic breast cancer showed that a new treatment combining T-DXd and pertuzumab reduced disease progression or death risk by 44%, with 15% achieving complete remission, compared to 8.5% with standard therapy; the findings will be ...
New 'Smart Bomb' Cancer Treatment Shows Significant Improvement in HER2-Positive Metastatic Breast Cancer
A clinical trial involving nearly 400 patients with HER2-positive metastatic breast cancer showed that a new treatment combining T-DXd and pertuzumab reduced disease progression or death risk by 44%, with 15% achieving complete remission, compared to 8.5% with standard therapy; the findings will be ...
Progress
48% Bias Score
Wales Rolls Out Cancer Drug Doubling Survival Time
The NHS in Wales now provides capivasertib, a new breast cancer drug shown to double life expectancy for half of women with oestrogen-fueled breast cancer when combined with hormone therapy; developed by Velindre Cancer Centre and Cardiff University, it's a significant advancement offering extended ...
Wales Rolls Out Cancer Drug Doubling Survival Time
The NHS in Wales now provides capivasertib, a new breast cancer drug shown to double life expectancy for half of women with oestrogen-fueled breast cancer when combined with hormone therapy; developed by Velindre Cancer Centre and Cardiff University, it's a significant advancement offering extended ...
Progress
56% Bias Score
Exercise Cuts Colon Cancer Death Risk by 37 Percent
A clinical trial involving 889 colon cancer patients across six countries revealed that 10 hours of weekly exercise reduced the risk of death by 37 percent over eight years, suggesting exercise as a significant adjuvant therapy.
Exercise Cuts Colon Cancer Death Risk by 37 Percent
A clinical trial involving 889 colon cancer patients across six countries revealed that 10 hours of weekly exercise reduced the risk of death by 37 percent over eight years, suggesting exercise as a significant adjuvant therapy.
Progress
56% Bias Score
Liquid Biopsies Improve Metastatic Breast Cancer Treatment
A new study published in The New England Journal of Medicine demonstrates that liquid biopsies can detect breast cancer mutations up to nine months earlier than imaging tests, enabling earlier treatment changes and improving patient outcomes; patients who switched treatments based on liquid biopsy r...
Liquid Biopsies Improve Metastatic Breast Cancer Treatment
A new study published in The New England Journal of Medicine demonstrates that liquid biopsies can detect breast cancer mutations up to nine months earlier than imaging tests, enabling earlier treatment changes and improving patient outcomes; patients who switched treatments based on liquid biopsy r...
Progress
52% Bias Score
New Drug Shows Significant Promise in Reducing Breast Cancer Progression
A clinical trial shows that the drug camizestrant reduces breast cancer progression by 52% compared to standard treatments, offering a potential breakthrough in precision medicine by using blood tests to detect treatment resistance early.
New Drug Shows Significant Promise in Reducing Breast Cancer Progression
A clinical trial shows that the drug camizestrant reduces breast cancer progression by 52% compared to standard treatments, offering a potential breakthrough in precision medicine by using blood tests to detect treatment resistance early.
Progress
48% Bias Score
Showing 37 to 48 of 171 results